Literature DB >> 18578477

Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human excitatory amino acid transporter subtype 2.

Emanuelle Sagot1, Anders A Jensen, Darryl S Pickering, Xiaosui Pu, Michelle Umberti, Tine B Stensbøl, Birgitte Nielsen, Zeinab Assaf, Bétina Aboab, Jean Bolte, Thierry Gefflaut, Lennart Bunch.   

Abstract

In the mammalian central nervous system (CNS), the action of sodium dependent excitatory amino acid transporters (EAATs) is responsible for termination of glutamatergic neurotransmission by reuptake of ( S) -glutamate (Glu) from the synaptic cleft. Five EAAT subtypes have been identified, of which EAAT1-4 are present in the CNS, while EAAT5 is localized exclusively in the retina. In this study, we have used an enantioselective chemo-enzymatic strategy to synthesize 10 new Glu analogues 2a- k ( 2d is exempt) with different functionalities in the 4 R-position and characterized their pharmacological properties at the human EAAT1-3. In particular, one compound, 2k, displayed a significant preference as inhibitor of the EAAT2 subtype over EAAT1,3. The compound also displayed very low affinities toward ionotropic and metabotropic Glu receptors, making it the most selective EAAT2 inhibitor described so far.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18578477     DOI: 10.1021/jm800091e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Structure-activity-relationship study of N-acyl-N-phenylpiperazines as potential inhibitors of the Excitatory Amino Acid Transporters (EAATs): improving the potency of a micromolar screening Hit is not truism.

Authors:  Tri Hv Huynh; Charles S Demmer; Bjarke Abrahamsen; Emil Marcher; Mikael Frykman; Anders A Jensen; Lennart Bunch
Journal:  Springerplus       Date:  2013-03-14

Review 2.  Glutamate as a neurotransmitter in the healthy brain.

Authors:  Y Zhou; N C Danbolt
Journal:  J Neural Transm (Vienna)       Date:  2014-03-01       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.